Início/GILD

Public research page

Market data comes from the live feed. The company research below uses verified public sources, but it is not a real-time personalized AI conclusion.

Analyze GILD in workspace
GILDNASDAQ/health care

Gilead Sciences, Inc.

$131.40Up+1,57 (+1,21%)
Research reviewed: 12 de jul. de 2026, 00:00 UTC
Research overview3-month price contextInvestment thesisKey catalystsLatest earnings researchRecent newsData and research sources

Research overview

Gilead Sciences, Inc. operates in Biotechnology within the health care sector. This profile tracks its company-specific earnings drivers, valuation conditions, and primary-source risks.

Ouverture
129,68
Haut
131,67
Bas
127,94
Capitalisation
163,14 Md
Ratio C/B
17.88
Plus haut sur 52 semaines
--
Dividende
2.530%
Dividende trimestriel
--

3-month price context

O gráfico mostra a tendência recente de 3 meses para ajudar usuários a entender a estrutura de curto prazo antes de abrir o workspace completo de pesquisa.

Investment thesis

Base case
Biktarvy leadership and Yeztugo adoption can sustain treatment and prevention growth. The base case remains conditional on hiv concentration staying manageable.
Bull case
Biktarvy leadership and Yeztugo adoption can sustain treatment and prevention growth. Trodelvy demand and acquired cell-therapy and antibody-drug-conjugate assets can diversify the portfolio. Livdelzi uptake can add a new growth leg alongside established antiviral franchises.
Bear case
Heavy reliance on HIV leaves earnings exposed to competition, payer pressure and patent transitions. Large acquisitions and acquired research charges can consume capital without producing approved products. Manufacturing complexity and intense competition can pressure patient access and cell-therapy sales.
Thesis invalidation
Reassess the thesis if heavy reliance on HIV leaves earnings exposed to competition, payer pressure and patent transitions.

Key catalysts

  • HIV franchise durability

    Biktarvy leadership and Yeztugo adoption can sustain treatment and prevention growth.

  • Oncology expansion

    Trodelvy demand and acquired cell-therapy and antibody-drug-conjugate assets can diversify the portfolio.

  • Liver-disease growth

    Livdelzi uptake can add a new growth leg alongside established antiviral franchises.

Principal risks

  • HIV concentration

    Heavy reliance on HIV leaves earnings exposed to competition, payer pressure and patent transitions.

  • Acquisition and IPR&D

    Large acquisitions and acquired research charges can consume capital without producing approved products.

  • Cell-therapy competition

    Manufacturing complexity and intense competition can pressure patient access and cell-therapy sales.

Latest earnings research

Q1 2026

Gilead's first-quarter 2026 results showed growth in its base business led by HIV, Trodelvy and Livdelzi, with Yeztugo launch progress and substantial pipeline investment and acquisition activity.

Valuation interpretation

  • HIV cash-flow durability provides support, but a higher growth interpretation requires successful diversification into prevention, oncology and liver disease.
  • Pipeline value should be weighed against acquisition spending, clinical attrition and the timing of patent erosion.

Peer research

ABBVAMGNVRTX

Recent news

Trefis · il y a 8 heures

Own Regeneron For Biotech Growth? Incyte Is Making Its Case.

Motley Fool · avant-hier

Many Investors Are Still Treating Gilead Sciences Like a Has-Been HIV Stock. 4 Drug Launches This Year Could Prove Them Wrong.

Zacks · il y a 3 jours

Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts

Motley Fool · il y a 3 jours

2 Recession-Resistant Dividend Stocks to Buy and Hold

Simply Wall St. · il y a 4 jours

Is Gilead Sciences (GILD) Cheap With Trodelvy And Yeztugo In Focus?

Simply Wall St. · il y a 5 jours

Gilead Sciences (GILD) Wins Trodelvy Approvals And Expands Texas CAR T Access

Data and research sources

Research updated: 12 de jul. de 2026, 00:00 UTC
3 verified sources
Gilead Sciences Announces First Quarter Financial ResultsGilead Sciences, Inc. · earningsVerified

Fetched: 12/07/2026, 0:00:00 UTC

Published: 07/05/2026, 00:00:00

Open original source
Gilead Sciences, Inc. Investor RelationsGilead Sciences, Inc. · companyVerified

Fetched: 12/07/2026, 0:00:00 UTC

Open original source
Gilead SEC filings and company factsU.S. Securities and Exchange Commission · filingVerified

Fetched: 12/07/2026, 0:00:00 UTC

Published: 07/05/2026, 00:00:00

Open original source

Continue in the research workspace

Keep GILD in context, run a multi-agent analysis, and monitor thesis changes.

Analyze GILD free

Conheça todo o sistema de análise

Cada etapa tem uma função clara e deixa um resultado auditável.

Metodologia de análiseLer relatórios de mercadoExplorar ações

Continue researching this stock

Analista de Mercado

Analista de Mercado se especializa na etapa de Observar dentro de Pesquisa central e organiza o contexto para os próximos papéis.

Analista Fundamentalista

Analista Fundamentalista se especializa na etapa de Observar dentro de Pesquisa central e organiza o contexto para os próximos papéis.

Analista de Notícias

Analista de Notícias se especializa na etapa de Observar dentro de Pesquisa central e organiza o contexto para os próximos papéis.

Gestor de Risco

Gestor de Risco se especializa na etapa de Monitorar dentro de Risco e monitoramento e organiza o contexto para os próximos papéis.